Trial Profile
Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Cancer vaccine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 02 Jan 2011 New trial record